S&P 500   3,118.26 (-0.12%)
DOW   27,926.20 (-0.39%)
QQQ   203.05 (-0.01%)
CGC   15.04 (+5.77%)
BABA   184.34 (-0.15%)
T   38.34 (-3.28%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
BAC   32.84 (-0.36%)
DIS   147.38 (-0.18%)
S&P 500   3,118.26 (-0.12%)
DOW   27,926.20 (-0.39%)
QQQ   203.05 (-0.01%)
CGC   15.04 (+5.77%)
BABA   184.34 (-0.15%)
T   38.34 (-3.28%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
BAC   32.84 (-0.36%)
DIS   147.38 (-0.18%)
S&P 500   3,118.26 (-0.12%)
DOW   27,926.20 (-0.39%)
QQQ   203.05 (-0.01%)
CGC   15.04 (+5.77%)
BABA   184.34 (-0.15%)
T   38.34 (-3.28%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
BAC   32.84 (-0.36%)
DIS   147.38 (-0.18%)
S&P 500   3,118.26 (-0.12%)
DOW   27,926.20 (-0.39%)
QQQ   203.05 (-0.01%)
CGC   15.04 (+5.77%)
BABA   184.34 (-0.15%)
T   38.34 (-3.28%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
BAC   32.84 (-0.36%)
DIS   147.38 (-0.18%)
Log in

Merck & Co., Inc. Stock Price, Forecast & Analysis (NYSE:MRK)

$84.37
+0.24 (+0.29 %)
(As of 11/19/2019 11:22 AM ET)
Today's Range
$84.26
Now: $84.37
$84.95
50-Day Range
$81.47
MA: $84.06
$86.44
52-Week Range
$70.89
Now: $84.37
$87.35
Volume186,516 shs
Average Volume9.15 million shs
Market Capitalization$214.80 billion
P/E Ratio19.44
Dividend Yield2.59%
Beta0.54
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP58933Y10
Phone908-740-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.29 billion
Cash Flow$6.17 per share
Book Value$10.34 per share

Profitability

Net Income$6.22 billion

Miscellaneous

Employees69,000
Outstanding Shares2,545,980,000
Market Cap$214.80 billion
Next Earnings Date2/7/2020 (Estimated)
OptionableOptionable

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.


Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, July 23rd. Shareholders of record on Monday, September 16th will be given a dividend of $0.55 per share on Monday, October 7th. This represents a $2.20 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date is Friday, September 13th. View Merck & Co., Inc.'s Dividend History.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. announced that its board has authorized a share buyback plan on Thursday, October 25th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 5.1% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's leadership believes its shares are undervalued.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Tuesday, October, 29th. The company reported $1.51 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.24 by $0.27. The company had revenue of $12.40 billion for the quarter, compared to the consensus estimate of $11.59 billion. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 48.16%. The business's revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the business earned $1.19 EPS. View Merck & Co., Inc.'s Earnings History.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Merck & Co., Inc..

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY19 earnings guidance on Tuesday, October, 29th. The company provided earnings per share guidance of $5.12-5.17 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.97. The company issued revenue guidance of $46.5-47.0 billion, compared to the consensus revenue estimate of $45.88 billion.

What price target have analysts set for MRK?

17 Wall Street analysts have issued 1 year price targets for Merck & Co., Inc.'s stock. Their forecasts range from $84.00 to $110.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $96.44 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price. View Analyst Price Targets for Merck & Co., Inc..

What is the consensus analysts' recommendation for Merck & Co., Inc.?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merck & Co., Inc..

What are Wall Street analysts saying about Merck & Co., Inc. stock?

Here are some recent quotes from research analysts about Merck & Co., Inc. stock:
  • 1. Mizuho analysts commented, "We like shares of MRK driven by KEYTRUDA’s penetration of global markets in multiple indications, which we believe will drive P&L transformation. While KEYTRUDA is growing in dominance, both in the market and on MRK’s P&L, we see MRK as having considerable runway (2028 LOE) to address concerns regarding concentration of revenue." (9/8/2019)
  • 2. According to Zacks Investment Research, "Merck’s new products like Keytruda, Lynparza, and Bridion are contributing meaningfully to the top line. Keytruda sales are gaining momentum with approval for additional indications, especially in the first-line lung cancer setting. Keytruda has strong growth prospects based on increased utilization, recent approvals for new indications and potential additional approvals worldwide. Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck. The company will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and products like Isentress (HIV), Zepatier (HCV) and Zostavax (vaccine) remains a concern. Merck’s shares have outperformed the industry this year. " (4/1/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate MRK 12-month PT of $95. We think there is upside to Keytruda sales estimates. Sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin-expansion opportunities, are underappreciated, in our view. Therefore, we expect upward earnings revisions and multiple expansion in 2019+ to drive MRK’s shares higher. Valuation Summary We arrive at our 12-month price target of $95 for Merck shares by using a blend of Base case analyses." (3/29/2019)

Has Merck & Co., Inc. been receiving favorable news coverage?

Media coverage about MRK stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck & Co., Inc. earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Merck & Co., Inc..

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 19,860,000 shares, a drop of 7.4% from the September 30th total of 21,440,000 shares. Based on an average trading volume of 8,190,000 shares, the days-to-cover ratio is currently 2.4 days. Currently, 0.8% of the company's shares are sold short. View Merck & Co., Inc.'s Current Options Chain.

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), AT&T (T), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), Verizon Communications (VZ), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Exxon Mobil (XOM) and General Electric (GE).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the folowing people:
  • Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 64)
  • Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 52)
  • Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 41)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
  • Mr. Adam H. Schechter, Special Advisor (Age 54)

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.42%), Massachusetts Financial Services Co. MA (0.40%), California Public Employees Retirement System (0.40%), Fisher Asset Management LLC (0.35%), Rhumbline Advisers (0.16%) and Robeco Institutional Asset Management B.V. (0.15%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Michael J Holston, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

Which institutional investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Manning & Napier Group LLC, Russell Investments Group Ltd., Nippon Life Insurance Co., Railway Pension Investments Ltd, State of Tennessee Treasury Department, Retirement Systems of Alabama and Varma Mutual Pension Insurance Co. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Kenneth C Frazier, Leslie A Brun, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

Which institutional investors are buying Merck & Co., Inc. stock?

MRK stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, USS Investment Management Ltd, Menora Mivtachim Holdings LTD., Public Employees Retirement Association of Colorado, Sumitomo Mitsui Trust Holdings Inc., ANTIPODES PARTNERS Ltd, CWM LLC and Fisher Asset Management LLC. View Insider Buying and Selling for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $84.37.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $214.80 billion and generates $42.29 billion in revenue each year. The company earns $6.22 billion in net income (profit) each year or $4.34 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.View Additional Information About Merck & Co., Inc..

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is http://www.merck.com/.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]


MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  795 (Vote Outperform)
Underperform Votes:  795 (Vote Underperform)
Total Votes:  1,590
MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel